JK-07 is under clinical development by Salubris Biotherapeutics and currently in Phase II for Systolic Heart Failure. According to GlobalData, Phase II drugs for Systolic Heart Failure have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how JK-07’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

JK-07 overview

JK-07 is under development for the treatment of amyotrophic lateral sclerosis (ALS), chronic heart failure with reduced ejection fraction (systolic heart failure) and heart failure with preserved ejection fraction (diastolic heart failure). It is administered through intravenous route of administration. The drug candidate is a recombinant human neuregulin 1-anti-human epidermal growth factor receptor 3 antibody fusion protein. It acts by targeting HER4/ErbB4.

Salubris Biotherapeutics overview

Salubris Biotherapeutics (SalubrisBio), a subsidiary of Shenzhen Salubris Pharmaceuticals Co Ltd, is a biotechnology company that discovers and develops novel antibody and protein-based drugs to treat cancer and cardiovascular diseases. It is investigating JK07, a recombinant fusion protein medicine targeting heart failure with reduced ejection fraction. The company is also evaluating JK08, a bispecific fusion protein formulation, JK10, a bispecific antibody-based drug and JK06, an antibody drug conjugant for the treatment of various oncology indications. Its approach focuses on activating the immune system and delivering anti-cancer agents directly to tumors. SalubrisBio is headquartered in Gaithersburg, Maryland, the US.

For a complete picture of JK-07’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 22 April 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.